1 |
van Doorn PA, Van den Bergh PYK, Hadden RDM.European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome [J].Eur J Neurol,2023, 30(12): 3646-3674.
|
2 |
Liu MS, Cui LY.Interpretation of Chinese guidelines for diagnosis and treatment of Guillain-Barré syndrome 2019 [J].Chin J Neurol, 2019,52(11): 873876.
|
3 |
Hughes RA, Swan AV, Raphaël JC, et al.Immunotherapy for Guillain-Barré syndrome: a systematic review [J].Brain, 2007, 130(Pt 9):22452257.
|
4 |
Misawa S, Kuwabara S, Sato Y, et al; Japanese Eculizumab Trial for GBS (JET-GBS) Study Group.Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial [J].Lance Neurol, 2018, 17(6): 519-529.
|
5 |
Barro C, Benkert P, Disanto G, et al.Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis [J].Brain, 2018, 141(8): 2382-2391.
|
6 |
Altmann P, De Simoni D, Kaider A.Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome [J].J Neuroinflammation, 2020, 17(1): 86.
|
7 |
Martín-Aguilar L, Camps-Renom P, Lleixà C, et al.Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients [J].J Neurol Neurosurg Psychiatry,2020:jnnp-2020-323899.
|
8 |
Keddie S, Smyth D, Keh RYS.Peripherin is a biomarker of axonal damage in peripheral nervous system disease [J].Brain, 2023, 146(11):4562-4573.
|
9 |
Zhu W, Li K, Cui T.Detection of anti-ganglioside antibodies in Guillain-Barré syndrome [J].Ann Transl Med, 2023, 11(7): 289.
|
10 |
Irie S, Saito T, Kanazawa N.Detection of serum anti-ganglioside antibodies by latex agglutination assay in Guillain-Barré syndrome:comparison with ELISA [J].Intern Med, 2003, 42(6): 490-495.
|
11 |
Keddie S, Smyth D, Keh RYS.Peripherin is a biomarker of axonal damage in peripheral nervous system disease [J].Brain, 2023, 146(11):4562-4573.
|
12 |
Febbo J, Revels J, Ketai L.Viral pneumonias [J].Radiol Clin North Am, 2022, 60(3): 383-397.
|
13 |
Ruuskanen O, Lahti E, Jennings LC.Viral pneumonia [J].Lancet,2011, 377(9773): 1264-1275.
|
14 |
Grasselli G, Calfee CS, Camporota L.European Society of Intensive Care Medicine Taskforce on ARDS.ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies [J].Intensive Care Med, 2023, 49(7): 727-759.
|
15 |
Ignacio Martin-Loeches I, Torres A, Nagavci B, et al.ERS/ESICM/ESCMID/ALAT guidelines for the management of severe communityacquired pneumonia [J].Intensive Care Med, 2023, 49(6): 615-632.
|
16 |
Bos LDJ, Ware LB.Acute respiratory distress syndrome: causes,pathophysiology, and phenotypes [J].Lancet, 2022, 400(10358): 1145-1156.
|
17 |
Gralinski LE, Sheahan TP, Morrison TE.Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis [J].mBio, 2018, 9(5): e01753-1818.
|
18 |
Bos LDJ, Ware LB.Acute respiratory distress syndrome: causes,pathophysiology, and phenotypes [J].Lancet, 2022, 400(10358): 1145-1156.
|
19 |
Matthay MA, Arabi Y, Arroliga AC, et al.A new global definition of acute respiratory distress syndrome [J].Am J Respir Crit Care Med,2024, 209(1): 37-47.
|
20 |
Ali YM, Lynch NJ, Shaaban AA.Inhibition of the lectin pathway of complement activation reduces LPS-induced acute respiratory distress syndrome in mice [J].Front Immunol, 2023, 14: 1192767.
|
21 |
Giudice V, Pagliano P, Vatrella A.Combination of Ruxolitinib and Eculizumab for treatment of severe SARS-CoV-2-related acute respiratory distress syndrome: a controlled study [J].Front Pharmacol,2020, 11: 857.
|
22 |
Raghunandan S, Josephson CD, Verkerke H, et al.Complement inhibition in severe COVID-19 acute respiratory distress syndrome [J].Front Pediatr, 2020, 8: 616731.
|